Harrow Health, Inc. (HROW) News
Filter HROW News Items
HROW News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest HROW News From Around the Web
Below are the latest news stories about HARROW INC that investors may wish to consider to help them evaluate HROW as an investment opportunity.
7 Short-Squeeze Stocks That Are Screaming for SpeculationWhile the concept of short-squeeze stocks has been all the rage throughout most of the pandemic-disruption cycle, we may have been doing this all wrong. |
Harrow Completes Transfer of the TRIESENCE® New Drug ApplicationNASHVILLE, Tenn., November 29, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application (NDA) for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a synthetic corticosteroid indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids as well as visualization during vitrectomy. |
Harrow to Present at Two Investor Conferences in NovemberNASHVILLE, Tenn., November 20, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in the following two upcoming conferences: |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning! |
Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call TranscriptHarrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript November 13, 2023 Harrow Health, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations were $0.03. Operator: Good afternoon, and welcome to Harrow’s Third Quarter 2023 Earnings Conference Call. My name is Betsy, and I will be your operator for today’s call. At this […] |
Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023Adjusted EBITDA Soars by 270% Year-Over-Year Amidst Operational Challenges |
Harrow Announces Third Quarter 2023 Financial ResultsNASHVILLE, Tenn., November 13, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2023. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period as well as the |
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023NASHVILLE, Tenn., October 30, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrow.com. Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provi |
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.NASHVILLE, Tenn., October 24, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for the following products: |
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.NASHVILLE, Tenn., September 29, 2023--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from "Harrow Health, Inc." to "Harrow, Inc." to align with the Company’s current five-year strategic plan, which includes an exclusive focus on eyecare pharmaceuticals. |